A phase 3 trial of BupiZenge 25 mg in advanced solid tumours, run by OncoZenge AB, now recruiting.
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. is a phase 3 interventional study registered as NCT07672236 by OncoZenge AB, with 150 participants planned, started 2026-07-07 and due to reach its primary completion in 2026-12-23. Interventions recorded: BupiZenge 25 mg and Lidocaine viscous 2%.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.